Nanoemulsion as Oral Drug Delivery - A Review

Author(s): Khaleel Basha Sabjan*, Syed Muzammil Munawar, Dhandayuthabani Rajendiran, Sugantha Kumari Vinoji, Kaviyarasu Kasinathan

Journal Name: Current Drug Research Reviews
Formerly: Current Drug Abuse Reviews

Volume 12 , Issue 1 , 2020

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: Objective: The stability and delivery of drugs remain one of the key hurdles in the present situation. The present study depends on the design of a novel nanoemulsion drugdelivery system that would encapsulate a drug and to improve drug stability. The charisma of nanotechnology is majorly due to the smallest particle size at the nanoscale.

Methods: Nanoemulsions attention is focused on emphasizing formulation aspect, method of preparation characterization techniques, evaluation parameters and various application of the nanoemulsions, several techniques to be used for the preparation of nanoemulsions like microfluidization, high-pressure homogenization, low energy emulsification and solvent evaporation method and their parameters to be characterized.

Results: The design of effective formulations for drugs is being applied to enhance the solubility and bioavailability of water-insoluble drugs. The nanosized droplets have led to considerable attraction for this formulation, for the delivery of hydrophilic as well as hydrophobic drugs as drug carriers because of their improved drug solubilization capacity, long shelf life, ease of preparation and improvement of bioavailability of drugs.

Conclusion: The application of these nanoformulation preparations, limitations, their advantages and disadvantages as nanoemulsions will solve the various problems that current therapeutic agents face and has opened a new scenario to formulate nanoemulsions with various therapeutic agents with heightened competence along with oral drug delivery to treat diseases in the near future.

Keywords: Nanoemulsion, oral drug delivery, nanotechnology, therapeutic agents, stability, emulsifiers.

[1]
Date AA, Nagarsenker MS. Parenteral microemulsions: An overview. Int J Pharm 2008; 355(1-2): 19-30.
[http://dx.doi.org/10.1016/j.ijpharm.2008.01.004] [PMID: 18295991]
[2]
Hussan KH. Nanoemulsion as a novel transdermal drug delivery system. Int J Pharm Sci Res 2011; 2(8): 1938-46.
[3]
Lachman L, Lieberman HA, Kanig JL. The theory and practice of industrial pharmacy. Edition 3. 510-1. 2018.
[4]
O’Hagan DT. Vaccine Adjuvant Humana Press. 214.
[5]
Bouchemal K, Briançon S, Perrier E, Fessi H. Nano-emulsion formulation using spontaneous emulsification: Solvent, oil and surfactant optimisation. Int J Pharm 2004; 280(1-2): 241-51.
[http://dx.doi.org/10.1016/j.ijpharm.2004.05.016] [PMID: 15265563]
[6]
Thakur A, Walia MK, Kumar SLH. Nanoemulsion in enhancement of bioavailability of poorly soluble drugs: A review. An Int Res J 2013; 4(1): 15-25.
[7]
Montserrat Roca F, Leverkusen DE. Nanoemulsion. United States patent application 20090324727 Assignee: Biofrontera Bioscience Gmbh (Leverkusen, De).
[8]
Arunkumar N, Deecaraman M, Rani C. Nanosuspension technology and its applications in drug delivery. Asian J Pharmaceut 2007; 124: 110.
[9]
Pey CM, Maestro A, Solè I, González C, Solans C, Gutierrez JM. Optimization of nano emulsions prepared by low energy emulsification methods at constant temperature using experimental designs. Coll Surf A Physico chem Engg Asp 2006; 288: 144-50.
[10]
Jafari SM, He Y, Bhandari B. Optimization of nanoemulsions production by microfluidization. Eur Food Res Technol 2007; 225: 733-41.
[http://dx.doi.org/10.1007/s00217-006-0476-9]
[11]
Floury J, Desrumaux AMAV, Legrand J. Effect of high pressure homogenization on methylcellulose as food emulsifier. J Food Eng 2003; 58: 227-38.
[http://dx.doi.org/10.1016/S0260-8774(02)00372-2]
[12]
Gothsch T, Finke JH, Beinert S, et al. Effect of microchannel geometry on high‐pressure dispersion and emulsification. Chem Eng Technol 2011; 34: 335-43.
[http://dx.doi.org/10.1002/ceat.201000421]
[13]
Shinoda K, Saito H. The effect of temperature on the phase equilibria and the type of dispersion of the ternary system composed of water, Cyclohexane and nonionic surfactant. J Colloid Interface Sci 1968; 26: 70-4.
[http://dx.doi.org/10.1016/0021-9797(68)90273-7]
[14]
Singh BP, Kumar B, Jain SK, Shafaat K. Development and characterization of a nanoemulsion gel formulation for transdermal delivery of carvedilol. Int J Drug Devpt Res 2012; 4(1): 151-61.
[15]
Shafiq S, Shakeel F, Talegaonkar S, Ahmad FJ, Khar RK, Ali M. Development and bioavailability assessment of ramipril nanoemulsion formulation. Eur J Pharm Biopharm 2007; 66(2): 227-43.
[http://dx.doi.org/10.1016/j.ejpb.2006.10.014] [PMID: 17127045]
[16]
Shafiq S, Shakeel F, Talegaonkar S, Ahmad FJ, Khar RK, Ali M. Development and bioavailability assessment of ramipril nanoemulsion formulation. Eur J Pharm Biopharm 2007; 66(2): 227-43.
[http://dx.doi.org/10.1016/j.ejpb.2006.10.014] [PMID: 17127045]
[17]
Devarajan V, Ravichandran V. Nanoemulsions: As modified drug delivery tool. Int J Comprehen Pharm 2011; 4(01): 1-6.
[18]
Patel and Joshi. An overview on nanoemulsion: A novel approach. Int J Pharm Sci Res 2012; 3(12): 4640-50.
[19]
Mishra RKumar, Soni GC, Mishra RP. A review article on nanoemulsion. WJ Pharm Sci 2011; 3(9): 258-74.
[20]
Haritha SP. Basha, Rao KP, Chakravarthi V. A brief introduction to methods of preparation, applications and characterisation of nanoemulsion drug delivery system. Ind J Res Pharm Biotech 2013; 1(1): 25-8.
[21]
Feng J, Roch M, Vigolo D, et al. Nanoemulsions obtained via bubble-bursting at a compound interface. Nat Phy 2014; 10(8): 606-12.
[22]
Fryd MM, Mason TG. Time-dependent nanoemulsion droplet size reduction by evaporative ripening. J Phys Chem Lett 2010; 1: 3349-53.
[http://dx.doi.org/10.1021/jz101365h]
[23]
Simonnet JT, Sonneville O, Lagret S. Nanoemulsion based on oxyethylenated or non-oxyethylatedsorbiton fatty esters, and its use in the cosmetic, dermatological and/or ophthalmological fields United States patent US6335022B1. 2002.
[24]
Simonnet JT, Sonneville O, Lagret S. Nanoemulsion based on ethoxylated fatty ethers or on ethoxylated fatty esters, and its use in the cosmetic, dermatological and/or ophthalmological fields United States patent US6375960. 2002.
[25]
Benita S, Lambert G. Method and composition for dry eye treatment United States patent US6656460. 2003.
[26]
Alloret FL, Sonneville O, Simonnet JT. Nanoemulsion containing nonionic polymers, and its uses United States patent US6998426. 2006.
[27]
Bague S, Philips B, Garrigue JS, Rabinovich-guilatt L, Lambert G. Oil-in-water type emulsion with low concentration of cationic agent and positive zeta potential European patent EP1655021. 2008.
[28]
Philips B, Bague S, Rabinovich-guilatt L, Lambert G. Ophthalmic emulsions containing an immunosuppressive agent European patent EP1809238. 2008.
[29]
Philips B, Bague S, Rabinovich-guilatt L, Lambert G. Ophthalmic emulsions containing prostaglandin European patent EP1827373. 2008.
[30]
Mitra AK, Velagaeti PR, Natesan S. Ophthalmic compositions comprising calcineurin inhibitors or mTOR inhibitors United States patent US0092665. 2009.
[31]
Alexis F, Zhang L, Radovic-Moreno A, et al. Poly (amino acid) targeting moieties United States patent US20090074828A1. 2009.
[32]
Domb AJ, Avramoff A, Prevzner V. Pro-nanodispersion for the delivery of cyclosporine United States patent US7732404. 2010.
[33]
Mitra AK, Velagaleti PR, Grau UM. Topical drug delivery for ophthalmic use WO2010144194. 2010.
[34]
Hara HN, Takeuchi HG. Liposome for delivery to posterior segment of eye and pharmaceutical for disease in posterior segment of eye United States patent US20110008421. 2011.
[35]
Bague S, Betty P, Garrigue JS, Guilatt LR, Lambert G. Oil-in-water type emulsion with low concentration of cationic agent and positive zeta potential United States patent US8298568. 2012.
[36]
Ketelson HA, Dassanayake NL, Carey TC, Meadows D. Use of nanoparticles as carriers for biocides in ophthalmic compositions United States patent US8097270. 2012.
[37]
Chauhan A, Gulsen D. Ophthalmic drug delivery system United States patent US8273366. 2012.
[38]
Ravi N. Hydrogel nanocompsites for ophthalmic applications United States patent US8153156B2. 2012.
[39]
Carli F, Baronian M, Schmid R, Chiellini E. Ophthalmic oil-in-water emulsions containing prostaglandins United States patent US8414904B2. 2013.
[40]
Bell STD, He Q, Potter DE. Intraocular delivery compositions and methods WO2004050065A1. 2004.
[41]
Sharma PC. A process for the preparation of oral insulin microcapsules Indian Patent 34/MAS/2002. 2002.
[42]
Ecanow B. Oral insulin and a method of making same US Patent 267749. 1990.
[43]
Burnside BA, Mattes CE, Guinness CMMC, Rudnic EM, Belendiuk GW. Oral insulin delivery US Patent 5824638. 1998.
[44]
Arbit E, Abbas R, Goldberg M, Woods TC, Dinn S, Wong V. Oral insulin therapy US Patent 10500822. 2008.
[45]
Arbit E, Goldberg M, Majuru S. Oral insulin therapies and protocol US Patent 20090253614. 2009.
[46]
Qian Y, Zhang LJ, Wu ZM. Enteric coated capsule containing cationic nanoparticles for oral insulin delivery US Patent 20130034602. 2013.
[47]
Gold Berg M, Arbit E. Night time oral insulin therapy US Patent 20060178296. 2006.
[48]
Sabetsky V. Oral insulin composition and methods of making and using there of U.S Patent 20100166855. 2010.
[49]
Zhang J. Biologically active oral preparation that can be site specific released in colon US Patent 10297527. 2005.
[50]
Gonda I, Rubsamen RM, Farr SJ. Inhaled insulin dosage control delivery enhanced by controlling total inhaled volume US Patent 950562. 2004.
[51]
Gonda I, Rubsamen RM, Farr SJ. Use of monomeric insulin as a means for improving bioavailability of inhaled insulin US Patent 792616. 1999.
[52]
Steiner SS, Pohl R. Rapid acting and prolonged acting inhaled insulin preparation US Patent 20070086925. 2006.
[53]
Schmitke JL, Chen D, Batycky RP, Edwards DA, Hrkach J. Particles for inhalation having rapid release properties US Patent 20080227690. 2007.
[54]
Brush H, Fu FN, Lipp MM, Chmitke JL. High load particles for inhalation having rapid release properties US Patent 20070123449. 2006.
[55]
Backstorm KGE, Dahlback CMO, Edman P, Johansson ACB. Therapeutic preparation for inhalation US Patent 09/665585. 2003.
[56]
Patton JS, Foster L, Platz RM. Methodand composition for pulmonary delivery of Insulin US Patent 821493. 1999.
[57]
Gonda I, Rubsamen RM. Method of delivering insulin lispro US Patent 069721. 1999.
[58]
Gonda I, Rubsamen RM, Farr SJ. Method of treating a diabetic patient by aerosolized administration of insulin US Patent 088534. 2000.
[59]
Backstorm KGE, Dahlback CMO, Edman P, Johansson ACB. Process for preparing composition for inhalation US Patent 858122. 1999.
[60]
Modi P. Pharmaceutical composition for buccal and pulmonary administration comprisingan alkali metal alkyl sulfate and at least 3 micelle-forming compounds US Patent 574504. 2002.
[61]
Modi P. Method for administering insulin to the buccal region US Patent 09538829. 2006.
[62]
Thompson W, Kelvin L. On the equilibrium of vapour at a curved surface of liquid. Philos Mag 1871; 42: 448-52.
[63]
Devarajan V, Ravichandran V. Nanoemulsions: As modified drug delivery tool Int J compr pharm 2011; 2(4): 1-6.
[64]
Nakajima HO, Miyuki T. Emulsified composition US patent 5,098,606. 1992.
[65]
Mittal KL, Dinesh O. Adsorption and aggregation of surfactants in solution European patent 0363928 B1. 1994.
[66]
Li P, Ghosh A, Wagner RF, Krill S, Joshi YM, Serajuddin ATM. Effect of combined use of nonionic surfactant on formation of oil-in-water microemulsions. Int J Pharm 2005; 288(1): 27-34.
[http://dx.doi.org/10.1016/j.ijpharm.2004.08.024] [PMID: 15607255]
[67]
Mbela TKM, Deharo E, Haemers A, Ludwig A. Submicron oil-in-water emulsion formulations for mefloquine and halofantrine: Effect of electric-charge inducers on antimalarial activity in mice. J Pharm Pharmacol 1998; 50(11): 1221-5.
[http://dx.doi.org/10.1111/j.2042-7158.1998.tb03337.x] [PMID: 9877306]
[68]
Bhalani VT, Satishchandra SP. Pharmaceutical composition for cyclosporines US Patent 5858401A. 1999.
[69]
Ghosh PK, Murthy RSR. Microemulsions: A potential drug delivery system. Curr Drug Deliv 2006; 3(2): 167-80.
[http://dx.doi.org/10.2174/156720106776359168] [PMID: 16611003]
[70]
Calvo P, Lopez R, Vila-Jato JL, Alonso MJ. Evaluation of cationic polymer-coated nanocapsules as ocular drug carriers. Col Poly Sci 1997; 275: 46-53.
[71]
Restel S, Cauwet-Martin D. Eur patent appl EP 842652 Al. 1998.
[72]
Schwarz JS, Weisspapir MR, Friedman DI. Enhanced transdermal delivery of diazepam by Submicron Emulsion (SME) creams. Pharm Res 1995; 12(5): 687-92.
[http://dx.doi.org/10.1023/A:1016255408348] [PMID: 7479554]
[73]
Ko KT, Needham TE, Zi H. Emulsion formulation of testosterone for nasal administration. J Microencap 1998; 15: 197-205.
[74]
Sznitowska M, Zurowska-Pryczkowska K, Janicki S, Järvinen T. Miotic effect and irritation potential of pilocarpine prodrug incorporated into a submicron emulsion vehicle. Int J Pharm 1999; 184(1): 115-20.
[http://dx.doi.org/10.1016/S0378-5173(99)00106-4] [PMID: 10425357]
[75]
Shinoda K, Lindman B. Organized surfactant systems: Microemulsions. Langmuir 1987; 3: 135-79.
[http://dx.doi.org/10.1021/la00074a001]
[76]
Wagner JG, Gerard ES, Kaiser DG. The effect of the dosage form on serum levels of indoxole. Clin Pharmacol Ther 1966; 7(5): 610-9.
[http://dx.doi.org/10.1002/cpt196675610] [PMID: 5957166]
[77]
Kim CK, Cho YJ, Gao ZG. Preparation and evaluation of biphenyl dimethyl dicarboxylate microemulsions for oral delivery. J Control Release 2001; 70(1-2): 149-55.
[http://dx.doi.org/10.1016/S0168-3659(00)00343-6] [PMID: 11166415]
[78]
Insulin Biosynthesis Secretion and Action Available from:. http://www.namrata.co/insulin-Biosynthesissecretion-and-action [Last Accessed on Aug 05, 2016].
[79]
Bouchemal K, Briançon S, Perrier E, Fessi H. Nano-emulsion formulation using spontaneous emulsification: Solvent, oil and surfactant optimisation. Int J Pharm 2004; 280(1-2): 241-51.
[http://dx.doi.org/10.1016/j.ijpharm.2004.05.016] [PMID: 15265563]
[80]
Shenoy DB, Tiwari SB. Nanoemulsion formulations for improved oral delivery of poorly soluble drugs. 9th annual NSTI nanotechnology conference and trade show North-Eastern University US.
[81]
Subhashis D, Satayanarayana J, Gampa VK. Nanoemulsion- A method to improve the solubility of lipophilic drugs. Pharmanest- Int J. Adv Pharm Sci 2011; 2: 72-83.
[82]
Lawrence MJ, Rees GD. Microemulsion-based media as novel drug delivery systems. Adv Drug Deliv Rev 2000; 45(1): 89-121.
[http://dx.doi.org/10.1016/S0169-409X(00)00103-4] [PMID: 11104900]
[83]
Shinoda K, Lindman B. Organized surfactant systems: Microemulsions. Langmuir 1987; 3: 135-79.
[http://dx.doi.org/10.1021/la00074a001]
[84]
Charles L, Attama AA. Current state of nanoemulsions in drug delivery. J Biomater Nanobiotechnol 2011; 2: 626-39.
[http://dx.doi.org/10.4236/jbnb.2011.225075]
[85]
Rao SV, Shao J. Self-Nanoemulsifying Drug Delivery Systems (SNEDDS) for oral delivery of protein drugs: I. Formulation development. Int J Pharm 2008; 362(1-2): 2-9.
[http://dx.doi.org/10.1016/j.ijpharm.2008.05.018] [PMID: 18650038]
[86]
Rao SV, Agarwal P, Shao J. Self-nanoemulsifying drug delivery systems (SNEDDS) for oral delivery of protein drugs: II. In vitro transport study. Int J Pharm 2008; 362(1-2): 10-5.
[http://dx.doi.org/10.1016/j.ijpharm.2008.05.016] [PMID: 18640797]
[87]
Rao SV, Yajurvedi K, Shao J. Self-Nanoemulsifying Drug Delivery System (SNEDDS) for oral delivery of protein drugs: III. in vivo oral absorption study. Int J Pharm 2008; 362(1-2): 16-9.
[http://dx.doi.org/10.1016/j.ijpharm.2008.05.015] [PMID: 18650037]
[88]
Shakeel F, Baboota S, Ahuja A, Ali J, Aqil M, Shafiq S. Nanoemulsions as vehicles for transdermal delivery of aceclofenac. AAPS PharmSciTech 2007; 8(4) E104
[http://dx.doi.org/10.1208/pt0804104] [PMID: 18181525]
[89]
Kim BS, Won M, Lee KM, Kim CS. In vitro permeation studies of nanoemulsions containing ketoprofen as a model drug. Drug Deliv 2008; 15(7): 465-9.
[http://dx.doi.org/10.1080/10717540802328599] [PMID: 18712624]
[90]
Tamilvanan S. Submicron emulsions as a carrier for topical (ocular and per-cutaneous) and nasal drug delivery. Ind J Pharm Educ 2004; 38(2): 73-8.
[91]
Mansour HM, Rhee YS, Wu X. Nanomedicine in pulmonary delivery. Int J Nanomed 2009; 4: 299-319.
[http://dx.doi.org/10.2147/IJN.S4937] [PMID: 20054434]
[92]
Lawrence MJ, Rees GD. Microemulsion-based media as novel drug delivery systems. Adv Drug Deliv Rev 2000; 45(1): 89-121.
[http://dx.doi.org/10.1016/S0169-409X(00)00103-4] [PMID: 11104900]
[93]
Sadurní N, Solans C, Azemar N, García-Celma MJ. Studies on the formation of O/W nano-emulsions, by low-energy emulsification methods, suitable for pharmaceutical applications. Eur J Pharm Sci 2005; 26(5): 438-45.
[http://dx.doi.org/10.1016/j.ejps.2005.08.001] [PMID: 16153811]
[94]
Pouton CW. Self-emulsifying drug delivery system, assessment of the efficiency of emulsification. Int J Pharm 2009; 27: 335-48.
[http://dx.doi.org/10.1016/0378-5173(85)90081-X]
[95]
Sukanya G, Mantry S, Anjum S. Review on nanoemulsions. Int J Innov Pharm Sci Res 2013; 1(2): 192-205.
[96]
Shafiq S, Shakeel F, Talegaonkar S, Ahmad FJ, Khar RK, Ali M. Development and bioavailability assessment of ramipril nanoemulsion formulation. Eur J Pharm Biopharm 2007; 66(2): 227-43.
[http://dx.doi.org/10.1016/j.ejpb.2006.10.014] [PMID: 17127045]
[97]
Tadros TF, Becher P. Encyclopedia of emulsion technology. New York: Marcel Dekker 1983; 4: pp. 129-285.
[98]
Shaji J, Joshi V. Self-Microemulsifying Drug Delivery System (SMEDDS) for improving bioavailability of hydrophobic drugs and its potential to give sustained release dosage forms. Ind J Pharm Educ 2005; 39(3): 130-5.
[99]
Nakajima H. Industrial applications of microemulsions. New York: Marcel Dekker 1997; 66: pp. 96-44788.
[100]
Benita S, Levy MY. Submicron emulsions as colloidal drug carriers for intravenous administration: Comprehensive physicochemical characterization. J Pharm Sci 1993; 82(11): 1069-79.
[http://dx.doi.org/10.1002/jps.2600821102] [PMID: 8289116]
[101]
Solans C, Esquena J, Forgiarini AM, et al. Absorption and Aggregation of Surfactants in Solution. New York: Marcel Dekker 2003; 2003: p. 109.
[102]
Mason TG, Krall AH, Gang H, Bibette J, Weitz DA. Encyclopedia of emulsion technology, edited by P Becher sMarcel Dekker. New York 1996; Vol. 4: p. 299.
[103]
Bhatt P, Madhav S. A detailed review on nanoemulsion drug delivery system. Int J Pharm Sci Res 2011; 2(10): 2482-9.
[104]
Gupta PK, Pandit JK, Kumar A, Swaroop P, Gupta S. Pharmaceutical nanotechnology novel nanoemulsion-high energy emulsification preparation, evaluation and application. Pharm Res 2010; 3: 117-38.
[105]
Date AA, Nagarsenker MS. Parenteral microemulsions: An overview. Int J Pharm 2008; 355(1-2): 19-30.
[http://dx.doi.org/10.1016/j.ijpharm.2008.01.004] [PMID: 18295991]
[106]
Trotta M. Influence of phase transformation on indomethacin release from microemulsions. J Control Release 1999; 60(2-3): 399-405.
[http://dx.doi.org/10.1016/S0168-3659(99)00094-2] [PMID: 10425344]
[107]
Figueroa Alvarez MJ. Transdermal delivery of methotrexate: Iontophoretic delivery from hydrogels and passive delivery from microemulsions. Int J Pharm 2001; 215: 57-65.
[http://dx.doi.org/10.1016/S0378-5173(00)00674-8] [PMID: 11250092]
[108]
Venkatesan N, Yoshimitsu J, Ito Y, Shibata N, Takada K. Liquid filled nanoparticles as a drug delivery tool for protein therapeutics. Biomaterials 2005; 26(34): 7154-63.
[http://dx.doi.org/10.1016/j.biomaterials.2005.05.012] [PMID: 15967493]
[109]
Insulin Biosynthesis Secretion and Action Available from:. http://www.namrata.co/insulin-Biosynthesis [Last Accessed on Aug 05, 2016].


open access plus

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 12
ISSUE: 1
Year: 2020
Page: [4 - 15]
Pages: 12
DOI: 10.2174/2589977511666191024173508

Article Metrics

PDF: 29
HTML: 5
EPUB: 1
PRC: 1